These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34030676)

  • 1. Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment.
    Lim YW; Coles GL; Sandhu SK; Johnson DS; Adler AS; Stone EL
    BMC Biol; 2021 May; 19(1):107. PubMed ID: 34030676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
    Niu M; Yi M; Wu Y; Lyu L; He Q; Yang R; Zeng L; Shi J; Zhang J; Zhou P; Zhang T; Mei Q; Chu Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):94. PubMed ID: 37573354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
    Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
    Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
    Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
    Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
    Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
    Quach HT; Hou Z; Bellis RY; Saini JK; Amador-Molina A; Adusumilli PS; Xiong Y
    Expert Opin Investig Drugs; 2022 Nov; 31(11):1187-1202. PubMed ID: 36448335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation.
    Yu Y; Liang Y; Xie F; Zhang Z; Zhang P; Zhao X; Zhang Z; Liang Z; Li D; Wang L; Chen Y; Sun L; Niu H; Wang Y
    Cancer Lett; 2024 Jul; 593():216964. PubMed ID: 38762193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.
    Takasaka N; Seed RI; Cormier A; Bondesson AJ; Lou J; Elattma A; Ito S; Yanagisawa H; Hashimoto M; Ma R; Levine MD; Publicover J; Potts R; Jespersen JM; Campbell MG; Conrad F; Marks JD; Cheng Y; Baron JL; Nishimura SL
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication.
    Horn LA; Chariou PL; Gameiro SR; Qin H; Iida M; Fousek K; Meyer TJ; Cam M; Flies D; Langermann S; Schlom J; Palena C
    J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35230974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
    Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
    Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells.
    Ding R; Liu S; Wang S; Chen H; Wang F; Xu Q; Zhu L; Dong X; Gu Y; Zhang X; Chao CC; Gao Q
    Theranostics; 2021; 11(10):4957-4974. PubMed ID: 33754038
    [No Abstract]   [Full Text] [Related]  

  • 20. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.